Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$11.08+0.18 (+1.65%)
Close on Nov 18, 2026Market cap $2.42BP/E –Yield –
Neogen revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Neogen's revenue for the twelve months ending Aug 31, 2026 was $883.99M, down 0.3% year over year. For fiscal 2026 it was $870.40M, down 2.7% from the year before. Over ten years it grew 10.5% a year on average. The highest annual figure on record is $924.20M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $870.40M | -2.7% |
| FY2025 | May 31, 2025 | $894.70M | -3.2% |
| FY2024 | May 31, 2024 | $924.20M | +12.4% |
| FY2023 | May 31, 2023 | $822.45M | +56.0% |
| FY2022 | May 31, 2022 | $527.16M | +12.5% |
| FY2021 | May 31, 2021 | $468.46M | +12.0% |
| FY2020 | May 31, 2020 | $418.17M | +1.0% |
| FY2019 | May 31, 2019 | $414.19M | +4.1% |
| FY2018 | May 31, 2018 | $397.93M | +11.1% |
| FY2017 | May 31, 2017 | $358.28M | +11.5% |
| FY2016 | May 31, 2016 | $321.28M | +13.5% |
| FY2015 | May 31, 2015 | $283.07M | +14.4% |
| FY2014 | May 31, 2014 | $247.41M | +19.2% |
| FY2013 | May 31, 2013 | $207.53M | +12.8% |
| FY2012 | May 31, 2012 | $184.05M | +6.6% |
| FY2011 | May 31, 2011 | $172.68M | +22.9% |
| FY2010 | May 31, 2010 | $140.51M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $222.80M | +6.5% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $225.30M | -0.1% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $211.20M | -4.4% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $224.69M | -2.8% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $209.20M | -3.6% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $225.50M | -4.8% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $221.00M | -3.4% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $231.26M | +0.7% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $216.96M | -5.3% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $236.77M | -2.1% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $228.81M | +4.8% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $229.63M | -0.2% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $228.99M | +73.0% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $241.81M | +72.6% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $218.26M | +70.2% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $230.03M | +76.2% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $132.35M | +3.2% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $140.09M | +9.9% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $128.24M | +9.9% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $130.52M | +13.5% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $128.31M | +17.4% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $127.43M | +16.8% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $116.71M | +16.9% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $115.00M | +6.7% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $109.33M | +7.8% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $109.07M | -0.6% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $99.87M | +2.2% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $107.80M | +0.7% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $101.42M | +1.8% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $109.76M | +1.5% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $97.70M | +2.9% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $107.10M | +6.4% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $99.63M | +5.7% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $108.12M | +9.4% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $94.90M | +7.4% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $100.70M | +11.0% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $94.21M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $98.85M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $88.39M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $90.72M | – |
See a number that looks wrong?